07:02 EDT Regulus (RGLS) to be acquired by Novartis (NVS) for $7.00 per share in cash
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGLS:
- Promising Phase 1b Results and Favorable Safety Profile Position Regulus’s Farabursen as a Strong Investment in ADPKD Treatment
- Promising Phase 1b Results and Future Prospects Drive Buy Rating for Regulus’s Farabursen
- Wells upgrades Regulus to Overweight after farabursen data reported
- Regulus upgraded to Overweight from Equal Weight at Wells Fargo
- Regulus Announces Positive Phase 1b Study Results